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Abstract
Background: Monoclonal antibodies targeting the PD-1/PD-L1 axis have gained increasing attention across many
solid tumors and hematologic malignancies due to their efficacy and favorable toxicity profile. With more than 1
agent now FDA-approved in a wide variety of tumor types, and with others in clinical trials, it is becoming more
common that patients present to clinic for potential treatment with a second PD-1/PD-L1 inhibitor.
Case presentation: In this report, we present two patients with renal cell carcinoma and one with melanoma who
received PD-1/PD-L1 inhibitors. Upon progression on their first-line PD-1/PD-L1 inhibitors, these patients received a
different PD-1 inhibitor (nivolumab in all cases) and all had progressive disease as their best response to the
subsequent PD-1 inhibitor. The reported clinical information focuses on the course of the disease and the
responses to all treatment regimens.
Conclusions: Clinicians should refrain from using multiple PD-1/PD-L1 inhibitors sequentially outside of clinical
trials until there is sufficient data to support this practice routinely. Prospective studies that allow prior treatment
with PD-1/PD-L1 are needed to validate the efficacy and safety of these drugs in the second line or later setting.
Furthermore, ongoing efforts that aim to identify mechanisms of resistance to immunotherapy will be informative
and may ultimately assist physicians in select the optimal treatment following progression on PD-1/PD-L1 inhibitor.
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Background
The programmed cell death protein-1 (PD-1) and its
ligands, PD-L1 and PD-L2, are part of a pathway that
cancer cells utilize to evade immune surveillance [1].
Monoclonal antibodies targeting the PD-1/PD-L1 axis
have demonstrated efficacy in numerous malignancies
[2–16]. Five of these agents (atezolizumab, nivolumab,
pembrolizumab, avelumab, and durvalumab) have gained
United States Food and Drug Administration (FDA)
approval for the treatment of non-small cell lung cancer
(NSCLC), renal cell carcinoma (RCC), melanoma,
urothelial carcinoma, head and neck squamous cell
carcinoma (HNSCC), Hodgkin’s Lymphoma, and Merkel
cell carcinoma [17]. With these agents and others in
development, physicians are more commonly faced with
the question of whether to treat patients with sequential
PD-1 blockade. While there is a general acceptance that
these drugs are “similar”, there are some subtle differ-
ences among them and many clinicians wonder if a sub-
sequent different PD-1 inhibitor can of be of any help to
patients with few therapeutic options after progression.
The outcomes of these patients in this expanding clinical
setting are largely unknown and have not been assessed
in clinical trials. In this report, we present the cases of
three patients (two with metastatic RCC and one with
melanoma) who initially responded to PD-1/PD-L1 block-
ade before progressing and later immediately progressed
upon re-treatment with a different PD-1 inhibitor.
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Case presentations
Case presentation 1
A 54-year-old man underwent a radical nephrectomy
which revealed an 11.5 cm pT2bN0M0 clear cell renal
cell carcinoma (ccRCC) on pathologic review. Four years
later, he was diagnosed with metastatic disease to the
lungs and hilar lymph nodes and began treatment with
an anti-PD-L1-based combination. The patient had a
best response of stable disease with tumor shrinkage and
remained on treatment for 15 months. He discontinued
therapy for progressive disease to the sacrum and the
cerebellum and subsequently underwent stereotactic
radiosurgery to the brain. Approximately 7 weeks after
the last dose of the anti-PD-L1-based combination, he
initiated treatment with 3 mg/kg nivolumab monother-
apy every 2 weeks. After the patient received 4 doses,
imaging showed progressive disease in the lung and hilar
lymph node after 7 weeks.
Case presentation 2
A 67-year-old male was diagnosed with pT2aN0M1 ccRCC
with multiple subcentimeter metastases to the lungs. The
patient initially underwent metastatectomy to remove a
0.6 cm tumor in the left upper lobe, but he experienced
progression 1 year later. An anti-PD-L1-based combination
was started and he had stable disease as best response with
tumor shrinkage and remained on treatment for 8 months
until he discontinued therapy for new liver metastases. He
then progressed after 2 cycles of axitinib. The patient
received 8 doses of 3 mg/kg nivolumab monotherapy every
2 weeks, 6 months after the last dose of the anti-PD-L1-
based combination. He experienced disease progression in
the lung, lymph nodes, and liver after 4 months.
Case presentation 3
A 78-year-old gentleman was diagnosed with stage IVM1c
BRAFV600mutant cutaneous melanoma with metastases to
the kidney, adrenal, and lymph node. The patient began
treatment with a vemurafenib, a BRAF inhibitor, but dis-
continued after two months for progressive disease. He
then progressed through treatment with cytotoxic chemo-
therapy, ipilimumab, and a combination of anti-BRAF/
MEK (dabrafenib plus trametinib) combination therapy.
He later received therapy with anti-PD-1 pembrolizumab
for 5 months before being discontinued for treatment-
related insulin-dependent diabetes mellitus, chronic prur-
itus, and joint pain. The patient had a complete response
on treatment. Approximately 20 months after the patient’s
last dose of pembrolizumab, he progressed and initiated
nivolumab every 2 weeks for 3 doses. Although the patient
continued on insulin for treatment of diabetes mellitus
throughout his time on nivolumab, neither the pruritus
nor the joint pain recurred after treatment with nivolu-
mab. Treatment was discontinued after 7 weeks due to
disease progression in the bilateral adrenal lesions, lymph
nodes, and a new lesion in the liver.
Discussion
Given the approval of different PD-1 and PD-L1 inhibitors
in several solid tumor and hematological malignancies as
of May 2017, it is anticipated that clinical decisions facing
patients and physicians as described above will become
more common. For example, there are already two PD-1
inhibitors, pembrolizumab and nivolumab, approved for
NSCLC and melanoma in both the first and second-line
setting. The shifting treatment paradigms in NSCLC and
other diseases such as melanoma and RCC are compli-
cated by the paucity of data for patients who fail PD-1/
PD-L1 inhibitors. This is partly because randomized trials
in which these agents were investigated in the second-line
setting or beyond, did not allow inclusion of patients who
had prior treatment with a PD-1 or PD-L1 inhibitor
[3–10, 12, 13, 15, 18]. Currently, there are numerous
ongoing and pending trials in RCC, melanoma, and
NSCLC that allow prior treatment with a PD-1/PD-
L1 inhibitor (Table 1). As many of these agents
target the same PD-1/PD-L1 axis, development of
resistance to one agent may plausibly lead to class
resistance and, therefore, the likelihood of response
to a second monotherapy agent given from the same
class could be low.
When successful, PD-1 blockade establishes a favor-
able equilibrium between the immune response to, and
immune evasion by, cancer cells [19]. In some situations,
patients who achieve an objective response on treatment
eventually experience disease progression. This acquired
resistance to immunotherapy, also known as secondary
tumor immune escape, has many plausible immuno-
logical explanations such as decreased intratumoral
T-cell infiltration, suboptimal T-cell activation, upregula-
tion of additional immune-checkpoints, or loss of tumor
immunogenicity [20, 21]. A recent genomic analysis
comparing pretreatment and progression biopsy samples
from melanoma patients who initially experienced an
objective response on anti-PD-1 therapy showed that
resistance was associated with: diminished antigen-
presentation due to a defective beta-2-microglubulin
(B2M) protein or impaired interferon-receptor signaling
due to truncated Janus Kinase 1 (JAK1) or Janus Kinase
2 (JAK2) proteins [22]. Another study comparing
differentially expressed genes between responders and
non-responders to immunotherapy in melanoma showed
that non-responders express a transcriptional signature
exhibiting simultaneous upregulation of genes involved
in the regulation of angiogenesis, cell adhesion, mesen-
chymal transition, extracellular matrix (ECM remodel-
ing), and wound-healing [23].
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Although many patients experience resistance after
responding to PD-1 or PD-L1 inhibitors, there may be
situations where re-treatment has plausible rationale.
Re-treatment with PD-1 blockade may be especially
effective in patients who discontinue the first PD-1 or
PD-L1 inhibitor for reasons other than disease progres-
sion. In fact, successful re-introduction of anti-PD-1
therapy after delayed tumor recurrence has been
reported in one patient with melanoma [24]. Data have
shown that even similar PD-1 agents, such as pembroli-
zumab and nivolumab, target different epitopes of PD-1
[25]. It is also reasonable to treat a patient with a PD-1
inhibitor after a PD-L1 inhibitor, or vice versa, given that
the PD-1 pathway has 3 inhibitory interactions (PD-
1:PD-L1, PD-1:PD-L2, and PD-L1:B7.1) and each of
these drugs only inhibit two of these [20]. A melanoma
mouse model has shown that there is a synergistic effect
of combining PD-1 and PD-L1 inhibition [26]. There is
also an ongoing clinical trial testing the combination of
PD-1 and PD-L1 inhibition [NCT02118337].
There are numerous opportunities to address mecha-
nisms of resistance to immunotherapy other than
retreatment with PD-1/PD-L1 monotherapy. For ex-
ample, anti-Vascular Endothelial Growth Factor (VEGF)
therapy has been shown to increase T-cell infiltration
[27] and preclinical data suggests that antibodies block-
ing T-cell co-stimulatory proteins [28–30] or low-dose
Interleukin-2 (IL-2) [31] may augment the immune re-
sponse to anti-PD-1/PD-L1. Currently, clinical trials are
ongoing which investigate Lymphocyte-activation gene 3
(LAG-3) and T-cell immunoglobulin and mucin-domain
containing-3 (TIM-3) blockade either as monotherapy
or in combination with an anti-PD-1 agent [NCT0
1968109, NCT02676869, NCT02817633, NCT02936102,
NCT02966548, NCT02460224, NCT03005782]. There is
also an early clinical trial investigating the synergy of IL-
2 and PD-1 inhibition in metastatic RCC
[NCT02989714]. Additionally, stereotactic radiation
therapy has been shown to increase the repertoire of
antigen-specific T-cells and antitumor antibodies, which
may increase the likelihood of the “abscopal effect” [32].
This suggests a possible synergy between radiotherapy
and immunotherapy, which is being investigated in
several ongoing clinical trials [NCT02821182, NCT0
2608385, NCT03050554, NCT02407171, NCT02843165,
NCT02837263].
However, it is unlikely possible to provide clinical trials
for all potential immunotherapy sequences. Therefore,
databases that captures real-life clinical data on the
safety and efficacy of anti-PD-1/PD-L1 therapy after
treatment with another PD-1/PD-L1 inhibitor may po-
tentially help to better characterize the outcomes of
these patients in an unselected setting. For example,
there is a United States-based registry for patients
treated with high-dose IL-2, Proleukin® Observational
Registry to Evaluate the Treatment Patterns and Clinical
Response in Malignancy (PROCLAIM), which adds real-
world experience for patients treated with IL-2 [33].
Similar registries for anti-PD-1/PD-L1 would also be
beneficial in the current immunotherapy era.
Conclusions
Currently, there is insufficient data to support treatment
with a different PD-1/PD-L1 inhibitor after progression
on PD-1 pathway blockade, and such practice should be
discouraged. Ideally, prospective studies that investigate
the efficacy and safety of a PD-1/PD-L1 inhibitor in the
second-line setting or later, which allows prior treatment
with one of these agents, are needed to validate the use of
sequential PD-1 blockade. Combined strategy such as dual
Table 1 Select ongoing and pending clinical trials that allow prior treatment with a PD-1 or PD-L1 inhibitor
Clinicaltrials.gov identifier Experimental agents Regimen targets Phase Tumor type
NCT02899078 Nivolumab + Ibrutinib PD-1 + BTK 1b/2 RCC
NCT02923531 Nivolumab + X4P-001 PD-1 + CXCR4 1b/2a RCC
NCT02963610* Pembrolizumab + Lenalidomide PD-1 + immunomodulatory 1/2 NSCLC
NCT03083808 Pembrolizumab + Docetaxel/Pemetrexed/Gemcitabine PD-1 + Chemotherapy 2 NSCLC
NCT03041181 Nivolumab + Docetaxel PD-1 + Chemotherapy 2 NSCLC
NCT02437136 Pembrolizumab + Entinostat PD-1 + HDAC 1b/2 NSCLC and melanoma
NCT02959437 Pembrolizumab + Azacitidine + Epacadostat PD-1 + Chemotherapy + IDO-1 1/2 NSCLC**
NCT03084640 Pembrolizumab + CMP-001 PD-1 + TLR9 1b/2 melanoma
NCT03014648 Atezolizumab PD-L1 2 NSCLC
PD-1 programmed cell death protein 1, BTK: Bruton’s tyrosine kinase, RCC: renal cell carcinoma, CXCR4: C-X-C chemokine receptor type 4, NSCLC: non-small cell
lung cancer, HDAC: histone deacetylases, IDO-1: Indoleamine 2,3-Dioxygenase 1, TLR9: Toll-like receptor 9, PD-L1 programmed death-ligand 1
*Prior treatment with anti-PD-1/PD-L1 is only allowed for the Phase 2 portion of this trial (which is only for NSCLC patients)
**Only the NSCLC cohort allows prior treatment with PD-1/PD-L1
Please note that this table was constructed using the following search terms on clinicaltrials.gov on 5/12/2017: “Nivolumab AND previously treated”,
“Pembrolizumab AND previously treated”, and “Atezolizumab AND previously treated”. After generating a list of trials, the eligibility criteria for each trial was
manually screened for inclusion in this table
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immune agents or combination of PD-1/PD-L1 non-
immune therapy appears to be more supported by preclin-
ical data and such trials represent a better opportunity to
improve outcomes. Furthermore, ongoing efforts that aim
to identify mechanisms of resistance to immunotherapy
will be informative and may ultimately assist physicians in
selecting a rational approach to the initial, and sequential,
treatment options for these patients.
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